Abstract
The development of therapeutic monoclonal antibodies (mAbs) has revolutionized the treatment of cancer along the last ten years. The best examples of their therapeutic efficacies have been obtained with rituximab for the treatment of CD20+ B-cell Non-Hodgkin Lymphoma (B-NHL), and several others antibodies with optimized bioactivities are now being developed for the treatment of various malignant hemopathies. We review here the main drugs developed in this field, and present some emerging concepts able to improve the bioactivities of the next generation of therapeutic mAbs.
Keywords: Cancer, lymphoma, therapy, antibodies, phosphoantigens
Current Drug Targets
Title: Emerging Concepts for the Treatment of Hematological Malignancies with Therapeutic Monoclonal Antibodies
Volume: 11 Issue: 7
Author(s): Aude-Helene Capietto, Samarh Keirallah, Emilie Gross, Nicolas Dauguet, Emilie Laprevotte, Christine Jean, Julie Gertner-Dardenne, Christine Bezombes, Anne Quillet-Mary, Mary Poupot, Loic Ysebaert, Guy Laurent and Jean-Jacques Fournie
Affiliation:
Keywords: Cancer, lymphoma, therapy, antibodies, phosphoantigens
Abstract: The development of therapeutic monoclonal antibodies (mAbs) has revolutionized the treatment of cancer along the last ten years. The best examples of their therapeutic efficacies have been obtained with rituximab for the treatment of CD20+ B-cell Non-Hodgkin Lymphoma (B-NHL), and several others antibodies with optimized bioactivities are now being developed for the treatment of various malignant hemopathies. We review here the main drugs developed in this field, and present some emerging concepts able to improve the bioactivities of the next generation of therapeutic mAbs.
Export Options
About this article
Cite this article as:
Capietto Aude-Helene, Keirallah Samarh, Gross Emilie, Dauguet Nicolas, Laprevotte Emilie, Jean Christine, Gertner-Dardenne Julie, Bezombes Christine, Quillet-Mary Anne, Poupot Mary, Ysebaert Loic, Laurent Guy and Fournie Jean-Jacques, Emerging Concepts for the Treatment of Hematological Malignancies with Therapeutic Monoclonal Antibodies, Current Drug Targets 2010; 11 (7) . https://dx.doi.org/10.2174/138945010791320845
DOI https://dx.doi.org/10.2174/138945010791320845 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances in the Development of Selective Mcl-1 Inhibitors for the Treatment of Cancer (2017-Present)
Recent Patents on Anti-Cancer Drug Discovery Rational Drug Development Using Gene-Targeted Agents and Their Application in Anti-Gene Radiotherapy
Current Genomics A Homodimer Model Can Resolve the Conundrum as to How Cytochrome P450 Oxidoreductase and Cytochrome b5 Compete for the Same Binding Site on Cytochrome P450c17
Current Protein & Peptide Science Histone Deacetylase Inhibitors as Potent Modulators of Cellular Contacts
Current Drug Targets Challenging the Current Approaches to Multiple Myeloma-Related Bone Disease: From Bisphosphonates to Target Therapy
Current Cancer Drug Targets Drug Combinatorial Therapies for the Treatment of KRAS Mutated Lung Cancers
Current Topics in Medicinal Chemistry Current Status and Perspectives in Peptide Receptor Radiation Therapy
Current Pharmaceutical Design Hypomethylation of Urokinase (uPA) Promoter in Breast and Prostate Cancer: Prognostic and Therapeutic Implications
Current Cancer Drug Targets Reactive Oxygen Species, Cancer and Anti-Cancer Therapies
Current Chemical Biology Targeting the Expression of Anti-Apoptotic Proteins by Antisense Oligonucleotides
Current Drug Targets Preclinical Studies of PROTACs in Hematological Malignancies
Cardiovascular & Hematological Disorders-Drug Targets Methods to Assess Tissue-Specific Distribution and Metabolism of Drugs
Current Drug Metabolism Improving Safety of Gene Therapy
Current Drug Safety Microenvironmental Regulation of Cancer Stem Cell Phenotypes
Current Stem Cell Research & Therapy Peripheral Benzodiazepine Receptor Ligands and their Anti-Inflammatory Effects
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Geriatric Evaluation of Oncological Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry pH-Sensitive PEGylated Liposomes Functionalized With a Fibronectin-Mimetic Peptide Show Enhanced Intracellular Delivery to Colon Cancer Cells
Current Pharmaceutical Biotechnology Protein Kinase C – Possible Therapeutic Target to Treat Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Immunological Targets in Inflammation from the Small Molecule Perspective
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Editorial: Looking Forward to Another Successful Year
Current Cancer Drug Targets